The Canada-based transdermal drug development firm Nuvo Research Inc and Daiichi-Ranbaxy, the Indian subsidiary of Japanese drug major Daiichi Sankyo has entered into an exclusive license agreement for the supply and distribution of Oxoferin, a topical wound healing agent in some Asian countries.
The details can be read here.
No comments:
Post a Comment